On December 12, 2023, Coya Therapeutics, Inc. closed the transaction. The securities are issued pursuant to exemption provided under Regulation D. The transaction included participation from 122 investors. The Company paid BTIG and Newbridge a fee based on gross proceeds from the sale of securities placed by each placement agent respectively and issued to Newbridge a warrant exercisable for 196,168 shares of Common Stock.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.21 USD | -2.96% | -5.41% | +10.80% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.80% | 120M | |
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- COYA Stock
- News Coya Therapeutics, Inc.
- Coya Therapeutics, Inc. announced that it has received $26.484515 million in funding